# Table 1 Model Parameters Values: Baseline, Ranges and Distributions for Sensitivity Analysis

| **Parameter** | **Base Case Value** | **Minimum Value** | **Maximum Value** | **Source** | **Distribution** |
| --- | --- | --- | --- | --- | --- |
| \*\*Cost (Per Cycle)\*\* |  |  |  |  |  |
| FOLFOX | 157.77 | 126.22 | 189.32 |  | GAMMA(100.00, 1.58) |
| FOLFIRI | 167.10 | 133.68 | 200.52 |  | GAMMA(100.00, 1.67) |
| Bevacizumab | 1425.84 | 1140.67 | 1711.01 |  | GAMMA(100.00, 14.26) |
| Subtyping Test Cost | 400.00 | 320.00 | 480.00 |  | GAMMA(100.00, 4.00) |
| Administration Cost | 406.50 | 325.20 | 487.80 |  | GAMMA(100.00, 4.07) |
| \*\*Adverse Event Cost\*\* |  |  |  |  |  |
| Leukopenia | 3485.23 | 2788.18 | 4182.28 |  | GAMMA(100.00, 34.85) |
| Diarrhea | 1792.82 | 1434.26 | 2151.38 |  | GAMMA(100.00, 17.93) |
| Vomiting | 502.69 | 402.15 | 603.23 |  | GAMMA(100.00, 5.03) |
| \*\*Adverse Event Incidence - With Bevacizumab\*\* |  |  |  |  |  |
| Leukopenia | 0.07 | 0.06 | 0.08 |  | BETA(92.93, 1234.64) |
| Diarrhea | 0.11 | 0.09 | 0.13 |  | BETA(88.89, 719.20) |
| Vomiting | 0.07 | 0.06 | 0.08 |  | BETA(92.93, 1234.64) |
| \*\*Adverse Event Incidence - Without Bevacizumab\*\* |  |  |  |  |  |
| Leukopenia | 0.04 | 0.03 | 0.05 |  | BETA(95.96, 2303.04) |
| Diarrhea | 0.31 | 0.25 | 0.37 |  | BETA(68.69, 152.89) |
| Vomiting | 0.31 | 0.25 | 0.37 |  | BETA(68.69, 152.89) |
| \*\*Adverse Event Incidence - Second Line\*\* |  |  |  |  |  |
| Leukopenia | 0.02 | 0.02 | 0.02 |  | BETA(97.98, 4801.02) |
| Diarrhea | 0.26 | 0.21 | 0.31 |  | BETA(73.74, 209.88) |
| Vomiting | 0.24 | 0.19 | 0.29 |  | BETA(75.76, 239.91) |
| \*\*Utility (Per Cycle)\*\* |  |  |  |  |  |
| Progression Free Survival | 0.85 | 0.68 | 1.00 |  | BETA(15.41, 2.72) |
| Overall Survival | 0.65 | 0.52 | 0.78 |  | BETA(32.96, 17.75) |
| \*\*Adverse Event Disutility\*\* |  |  |  |  |  |
| Leukopenia | 0.45 | 0.36 | 0.54 | BRTYA | alpha\_u\_AE1, beta\_u\_AE1 (54.55, 66.67) |
| Diarrhea | 0.19 | 0.15 | 0.23 | BETA | alpha\_u\_AE2, beta\_u\_AE2 (80.81, 344.51) |
| Vomiting | 0.36 | 0.29 | 0.43 | BETA | alpha\_u\_AE3, beta\_u\_AE3 (63.64, 113.14) |
| \*\*Hazard Ratios\*\* |  |  |  |  |  |
| PFS to OS under the Experimental Strategy | 0.68 | 0.53 | 0.87 | [@smeets2018] | rlnorm() |
| PFS to Dead under the Experimental Strategy | 0.65 | 0.49 | 0.86 | [@smeets2018] | rlnorm() |
| \*\*Probability of Dying under Second-Line Treatment\*\* | 0.17 | 0.12 | 0.22 |  | BETA(36.69, 179.13) |
| \*\*Discount Rate\*\* |  |  |  |  |  |
| Costs | 0.00 | 0.00 | 0.08 |  |  |
| Outcomes | 0.00 | 0.00 | 0.08 |  |  |